Medicinal Cannabis Sativex and Bedrocan are now available in many European countries, and several have infrastructure in place to supply patients with medicinal cannabis. So which countries are moving with the times, and which are dragging their heels? Where are medicinal and recreational users most (and least) free to utilize their drug of choice? Let’s take a look at the facts.

Erin said on Monday that MGC's first range of 15 cannabidiol-based cosmetic products - facial creams, soaps, toners and cleansing masks - is set for commercial launch over the coming months.

"Erin Resources is pleased to announce the imminent launch by MGC Pharmaceuticals Ltd of its initial CBD (cannabidiol) cosmetics product range, with first sales expected to occur by December 2015," Erin said on Monday.

There has been a flurry of pot deals on the ASX

The company attempting to backdoor list cannabis play MGC Pharmaceuticals this morning announced it had entered into a $60 million offtake deal with European cosmetics company Natura Laboratories.

Erin Resources shares bounced 0.3 cents to 2.2 cents on the news, which will see MGC supply the pharmaceutical for a minimum supply of 300kg of resin per year for a four-year minimum term.

It claimed it is the first first ASX-related cannabis or hemp company to sign a wholesale cannabis supply contract

An Australian pharmaceutical company, the most recent "pot stock" to trade on the ASX, has become one of the first local players to be granted a license to grow marijuana for medicinal purposes. 

MGC Pharmaceuticals, which is operated out of Israel, will be allowed to grow, process, import and export cannabis from Slovenia, where the government has legalised the practice.

Fellow Australian cannabis producer, AusCann, secured permission to grow and export marijuana on Norfolk Island in May. The difference between the two producers is MGC hopes to produce a product for the cosmetic industry whereas AusCann is targetting pain relief.